{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T13:01:35Z","timestamp":1769000495206,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,8,6]],"date-time":"2018-08-06T00:00:00Z","timestamp":1533513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s00280-018-3659-8","type":"journal-article","created":{"date-parts":[[2018,8,6]],"date-time":"2018-08-06T00:51:41Z","timestamp":1533516701000},"page":"717-721","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Comparison of levetiracetam with phenytoin for the prevention of intravenous busulfan-induced seizures in hematopoietic cell transplantation recipients"],"prefix":"10.1007","volume":"82","author":[{"given":"Kana","family":"Akiyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6773-4653","authenticated-orcid":false,"given":"Tetsuo","family":"Kume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Fukaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikue","family":"Shiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terukazu","family":"Enami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raine","family":"Tatara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihiro","family":"Shino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,6]]},"reference":[{"key":"3659_CR1","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/bmt.2008.372","volume":"43","author":"SW Kim","year":"2009","unstructured":"Kim SW, Mori SI, Tanosaki R, Fukuda T, Kami M, Sakamaki H, Yamashita T, Kodera Y, Terakura S, Taniguchi S, Miyakoshi S, Usui N, Yano S, Kawano Y, Nagatoshi Y, Harada M, Morishima Y, Okamoto S, Saito AM, Ohashi Y, Ueda R, Takaue Y (2009) Busulfex (i.v. BU) and CY regimen before SCT: Japanese-targeted phase II pharmacokinetics combined study. Bone Marrow Transplant 43:611\u2013617","journal-title":"Bone Marrow Transplant"},{"key":"3659_CR2","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1182\/blood-2013-08-519009","volume":"122","author":"C Bredeson","year":"2013","unstructured":"Bredeson C, LeRademacher J, Kato K, Dipersio JF, Agura E, Devine SM, Appelbaum FR, Tomblyn MR, Laport GG, Zhu X, McCarthy PL, Ho VT, Cooke KR, Armstrong E, Smith A, Rizzo JD, Burkart JM, Pasquini MC (2013) Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood 122:3871\u20133878","journal-title":"Blood"},{"key":"3659_CR3","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1200\/JCO.2011.40.2362","volume":"31","author":"JH Lee","year":"2013","unstructured":"Lee JH, Joo YD, Kim H, Ryoo HM, Kim MK, Lee GW, Lee JH, Lee WS, Park JH, Bae SH, Hyun MS, Kim DY, Kim SD, Min YJ, Lee KH (2013) Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. J Clin Oncol 31:701\u2013709","journal-title":"J Clin Oncol"},{"key":"3659_CR4","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1592\/phco.28.12.1502","volume":"28","author":"AL Eberly","year":"2008","unstructured":"Eberly AL, Anderson GD, Bubalo JS, McCune JS (2008) Optimal prevention of seizures induced by high-dose busulfan. Pharmacotherapy 28:1502\u20131510","journal-title":"Pharmacotherapy"},{"key":"3659_CR5","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1177\/1078155216651128","volume":"23","author":"AE Floeter","year":"2017","unstructured":"Floeter AE, McCune JS (2017) Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients. J Oncol Pharm Pract 23:344\u2013349","journal-title":"J Oncol Pharm Pract"},{"key":"3659_CR6","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s12185-015-1756-6","volume":"101","author":"M Sato","year":"2015","unstructured":"Sato M, Kako S, Matsumoto K, Oshima K, Akahoshi Y, Nakano H, Ugai T, Yamasaki R, Wada H, Ishihara Y, Sakamoto K, Kawamura K, Ashizawa M, Terasako-Saito K, Kimura S, Nakasone H, Kikuchi M, Tanihara A, Yamazaki R, Tanaka Y, Kanda J, Nishida J, Morita K, Kanda Y (2015) Pharmacokinetics study of once-daily intravenous busulfan in conditioning regimens for hematopoietic stem cell transplantation. Int J Hematol 101:497\u2013504","journal-title":"Int J Hematol"},{"key":"3659_CR7","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s11096-013-9768-x","volume":"35","author":"MS Diaz-Carrasco","year":"2013","unstructured":"Diaz-Carrasco MS, Olmos R, Blanquer M, Velasco J, S\u00e1nchez-Salinas A, Moraleda JM (2013) Clonazepam for seizure prophylaxis in adult patients treated with high dose busulfan. Int J Clin Pharm 35:339\u2013343","journal-title":"Int J Clin Pharm"},{"key":"3659_CR8","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1200\/JCO.1996.14.5.1484","volume":"14","author":"JT Slattery","year":"1996","unstructured":"Slattery JT, Kalhorn TF, McDonald GB, Lambert K, Buckner CD, Bensinger WI, Anasetti C, Appelbaum FR (1996) Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J Clin Oncol 14:1484\u20131494","journal-title":"J Clin Oncol"},{"key":"3659_CR9","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00280-004-0922-y","volume":"55","author":"ME Jonge de","year":"2005","unstructured":"de Jonge ME, Huitema AD, van Dam SM, Beijnen JH, Rodenhuis S (2005) Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin. Cancer Chemother Pharmacol 55:507\u2013510","journal-title":"Cancer Chemother Pharmacol"},{"key":"3659_CR10","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/pbc.24126","volume":"59","author":"S Soni","year":"2012","unstructured":"Soni S, Skeens M, Termuhlen AM, Bajwa RP, Gross TG, Pai V (2012) Levetiracetam for busulfan-induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation. Pediatr Blood Cancer 59:762\u2013764","journal-title":"Pediatr Blood Cancer"},{"key":"3659_CR11","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/petr.12249","volume":"18","author":"A Yazal Erdem","year":"2014","unstructured":"Yazal Erdem A, Az\u0131k F, Tavil B, Teber S, Tun\u00e7 B, U\u00e7kan D (2014) Busulfan triggers epileptic seizures under levetiracetam and valproic acid therapy. Pediatr Transplant 18:412\u2013413","journal-title":"Pediatr Transplant"},{"key":"3659_CR12","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.clinthera.2006.05.004","volume":"28","author":"S Ramael","year":"2006","unstructured":"Ramael S, De Smedt F, Toublanc N, Otoul C, Boulanger P, Riethuisen JM, Stockis A (2006) Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. Clin Ther 28:734\u2013744","journal-title":"Clin Ther"},{"key":"3659_CR13","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1007\/s40262-017-0537-1","volume":"56","author":"J Tan","year":"2017","unstructured":"Tan J, Paquette V, Levine M, Ensom MHH (2017) Levetiracetam clinical pharmacokinetic monitoring in pediatric patients with epilepsy. Clin Pharmacokinet 56:1267\u20131285","journal-title":"Clin Pharmacokinet"},{"key":"3659_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0920-1211(02)00250-4","volume":"53","author":"E Perucca","year":"2003","unstructured":"Perucca E, Gidal BE, Balt\u00e8s E (2003) Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. Epilepsy Res 53:47\u201356","journal-title":"Epilepsy Res"},{"key":"3659_CR15","unstructured":"Common Terminology Criteria for Adverse Events, version 4.0. NCI, NIH, DHHS. \n                    https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf\n                    \n                  . Accessed 8 May 2017"},{"key":"3659_CR16","doi-asserted-by":"publisher","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","volume":"118","author":"GB McDonald","year":"1993","unstructured":"McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, Hardin BJ, Shulman HM, Clift RA (1993) Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 118:255\u2013267","journal-title":"Ann Intern Med"},{"key":"3659_CR17","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1007\/s12185-016-2098-8","volume":"104","author":"E Leon-Rodriguez","year":"2016","unstructured":"Leon-Rodriguez E, Rivera-Franco MM (2016) Minimal incidence of neurotoxicity without prophylaxis during busulfan-based conditioning regimen in patients undergoing stem cell transplantation. Int J Hematol 104:644\u2013646","journal-title":"Int J Hematol"},{"key":"3659_CR18","first-page":"363","volume":"7","author":"R Camara De La","year":"1991","unstructured":"De La Camara R, Tomas JF, Figuera A, Berberana M, Fernandez-Ra\u00f1ada JM (1991) High dose busulfan and seizures. Bone Marrow Transplant 7:363\u2013364","journal-title":"Bone Marrow Transplant"},{"key":"3659_CR19","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.bbmt.2013.10.028","volume":"20","author":"D Caselli","year":"2014","unstructured":"Caselli D, Rosati A, Faraci M, Podda M, Ripaldi M, Longoni D, Cesaro S, Lo Nigro L, Paolicchi O, Maximova N, Menconi MC, Ziino O, Cicalese MP, Santarone S, Nesi F, Aric\u00f2 M, Locatelli F, Prete A (2014) Risk of seizures in children receiving busulphan-containing regimens for stem cell transplantation. Biol Blood Marrow Transplant 20:282\u2013285","journal-title":"Biol Blood Marrow Transplant"},{"key":"3659_CR20","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1053\/bbmt.2002.v8.pm11939604","volume":"8","author":"BS Andersson","year":"2002","unstructured":"Andersson BS, Kashyap A, Gian V, Wingard JR, Fernandez H, Cagnoni PJ, Jones RB, Tarantolo S, Hu WW, Blume KG, Forman SJ, Champlin RE (2002) Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 8:145\u2013154","journal-title":"Biol Blood Marrow Transplant"},{"key":"3659_CR21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(08)70313-9","volume":"10","author":"M Saito","year":"2009","unstructured":"Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet oncol 10:115\u2013124","journal-title":"Lancet oncol"},{"key":"3659_CR22","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/phar.1294","volume":"33","author":"M Uchida","year":"2013","unstructured":"Uchida M, Kato K, Ikesue H, Ichinose K, Hiraiwa H, Sakurai A, Muta T, Takenaka K, Iwasaki H, Miyamoto T, Teshima T, Shiratsuchi M, Suetsugu K, Nagata K, Egashira N, Akashi K, Oishi R (2013) Efficacy and safety of aprepitant in allogeneic hematopoietic stem cell transplantation. Pharmacotherapy 33:893\u2013901","journal-title":"Pharmacotherapy"},{"key":"3659_CR23","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1248\/bpb.b12-01012","volume":"36","author":"M Uchida","year":"2013","unstructured":"Uchida M, Ikesue H, Miyamoto T, Kato K, Suetsugu K, Ichinose K, Hiraiwa H, Sakurai A, Takenaka K, Muta T, Iwasaki H, Teshima T, Shiratsuchi M, Egashira N, Akashi K, Oishi R (2013) Effectiveness and safety of antiemetic aprepitant in Japanese patients receiving high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation. Biol Pharm Bull 36:819\u2013824","journal-title":"Biol Pharm Bull"},{"key":"3659_CR24","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.bbmt.2015.09.014","volume":"22","author":"H Chaudhry","year":"2016","unstructured":"Chaudhry H, Bruce AJ, Wolf RC, Litzow MR, Hogan WJ, Patnaik MS, Kremers WK, Phillips GL, Hashmi SK (2016) The incidence and severity of oral mucositis among allogeneic hematopoietic stem cell transplantation patients: a systematic review. Biol Blood Marrow Transplant 22:605\u2013616","journal-title":"Biol Blood Marrow Transplant"},{"key":"3659_CR25","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/bmt.2015.238","volume":"51","author":"S Ben Barouch","year":"2016","unstructured":"Ben Barouch S, Cohen O, Vidal L, Avivi I, Ram R (2016) Busulfan fludarabine vs busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: systematic review and meta-analysis. Bone Marrow Transplant 51:232\u2013240","journal-title":"Bone Marrow Transplant"},{"key":"3659_CR26","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, Apperley J, Slavin S, Pasquini M, Sandmaier BM, Barrett J, Blaise D, Lowski R, Horowitz M (2009) Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 15:1628\u20131633","journal-title":"Biol Blood Marrow Transplant"},{"key":"3659_CR27","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s00228-009-0652-5","volume":"65","author":"F L\u00e9ger","year":"2009","unstructured":"L\u00e9ger F, Nguyen L, Puozzo C (2009) Exposure equivalence between IV (0.8 mg\/kg) and oral (1 mg\/kg) busulfan in adult patients. Eur J Clin Pharmacol 65:903\u2013911","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-018-3659-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3659-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3659-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T19:06:41Z","timestamp":1565032001000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-018-3659-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,6]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["3659"],"URL":"https:\/\/doi.org\/10.1007\/s00280-018-3659-8","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,6]]},"assertion":[{"value":"2 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Shizuoka Cancer Center institutional review board approved our study design and publication of the results. The Shizuoka Cancer Center ethics committee waived the requirement for informed consent because of the retrospective nature of the study. This article does not contain any studies with animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}